Spero Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Spero Therapeutics

07/05/2024 12:53

* Spero Therapeutics Inc  SPRO.OQ   SPRO.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 9
(estimated) for the period ending January 1 0001
    * The Cambridge Massachusetts-based  company is expected to
report
a 940.8% increase in revenue to $21.533 million from $2.07
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Spero Therapeutics Inc
is for
a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 300.0% in the last three months. ​
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $7.50​, above​ its last closing price
of $1.66. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.23       -0.10      0.96      Beat    1,060
 Sep. 30 2023  -0.02       -0.03      0.04      Beat    233.3
 Jun. 30 2023  -0.33       -0.34      -0.23     Beat    33​
 Jan. 1 0001   -0.33       -0.33      -0.25     Beat    25
 ​​Dec.                    0.04       0.55      Beat    1,169.
 31 2022                                                3
 Sep. 30 2022  -0.31       -0.30      -0.33     Missed  -8.8​
 Jun. 30 2022  -0.92       -0.93      -0.87     Beat    6.1
 Mar. 31 2022  -0.86       -0.87      -1.01     Missed  -16.2
 This summary was machine generated May 7 at 11:53 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)